The association of DM.HT and JRA has not been previously recorded.The purpose of this comnunication Is to report our preliminary findings In a 14 year old Haitian girl who developed In sulln-dependent DM at age 6 yrs. goiter at 9 yrs. and polyarticular JRA at 12 yrs.No evidence of lridocyclitis was present.Fo1 lowing thyroid and gold therapy the goiter regressed and the arthritis improved.There was a family history of DM and goiter i the mother and of DM in maternal relatives.lnvestlgations reveal
ed normal T4;antlmicrosomal thyroid antibodies (1:25,000 and 1: 7,OOO);antinuclear antibodies (1 :32.768 and 1 :1,024) ;rheumatoid factor (1 :320 and 1 :640) ;high-normal C3 (240mg%) and elevated C4 (240mg%) ;normal IgA and 1gM.elevated 1gG;elevated gannna globulin normal CBC peri pheral smear and serum B12;normal adrenal respons to ACTH stimulatlon;HL-A.A-28,A-9,B-27,B-7,CW-2;eievated ESR (33 and 26 mn/hr) ; and evidence of JRA on wrist x-ray.These findings an autolmnune disorder. DM in this patient lends suport to the concept that OM may itself be a disease of autoimnun rigln.We believe this to be the first report of the coexistence nd concurrent expression of DM, HT and JRA in one individual.
ETABOLIC CLEARANCE RATE OF OXYTOCIN I N MATERNAL AND ETAL SHEEP. T.H. G l a t z , R.E. Weitzman, 298 a t h a n i e l s z , and D.A. Fisher. Fetal-Maternal Research Laboratories. UCLA-Harbor General H o s p i t a l , Torrance, CA. E I Simultaneous maternal and f e t a l plasma o x y t o c i n (OXY) concn.
(pU/ml) were measured by radioimnunoassay b e f o r e and d u r i n g continuous i n f u s i o n o f s y n t h e t i c OXY t o steady s t a t e c o n d i t i o n s i n t l ewe o r f e t u s ( g e s t a t i o n a l age 124-140 days; a t l e a s t 5 days p o s t surgery; estimated f e t a l w t . 3 kg). I n f u s i o n Rate: F e t a l OXY I n f u s i o n Maternal OXY I n f u s i o n Fetal(N-5) Maternal (N=4) Maternal (l4=4) F e t a l (N=3 B a s e l i n e 1. 0.9'0.2 47.3i6.4 2.0t0.8 F e t a l metabolic clearance r a t e s (MCR i n ml/kg/min) were calcul a t e d t o be 18.1 t 1.1 and 15.0'1.3 a t the two i n f u s i o n r a t e s ; maternal MCR were 1 2 . 7 t 2.8 and 13.4 + 2.3, r e s p e c t i v e l y . Exami n a t i o n o f simultaneous f e t a l and maternal b a s e l i n e OXY concent r a t i o n s r e v e a l e d t h a t f e t a l l e v e l s were s i n i f i c a n t l y h i g h e r than maternal: 1.9'0.2 vs 0 . 7 1 0 . 1 (p<.05q.
Continuous monit o r i n g o f u t e r i n e pressure revealed t h a t u t e r i n e c o n t r a c t i o n s were induced by maternal i n f u s i o n o f 800 ~U / k g / m i n ; no u t e r i n e c o n t r a c t i o n s were induced by f e t a l i n f u s i o n . Conclusions based on these data are: 1 ) plasma OXY l e v e l s exceed maternal l e v e l s i n f e t u s e s o f 124-140 days g e s t a t i o n ; 2) t r a n s p l acental passage o f OXY i s minimal i n b o t h M-F and F-M d i r e c t i o n s ; 3) maternal and f e t a l MCR o f OXY a r e s i m i l a r and u n r e l a t e d t o plasma OXY 1 eve1 s. A newly developed continuous glucose monitor (CGM) incorporates a non-thrombogenic blood withdrawal system and a glucose electrode which generates a continuous tracing of real blood glucose (BG) during an Arginine-Insulin GH Stimulation Test (AIST) which was administered to seven children with short stature.
The intravenous infusion of arginine was associated with an increase of BG from a baseline of 83 + 10.9 to 107.7 + 14.9 (mg/ 100 ml + 1 SD). The peak level was reached 26.3 + 6.5 minutes, and returned to baseline 51.3 + 9.5 minutes, after the IV inject ion.
The nadir in BG occurred 30.4 + 8.5 minutes after IV insulin.
The baseline level of 76.6 + 10.1 mg/100 ml + 1 SD fell to 29.12 6.2. The BG returned to normal 57.2 + 7.5 minutes after the IV injection. Symptoms of hypoglycemia may force premature termination of the AIST. In two of the patients the AIST was continued despite symptoms because the BG level was increasing at the time. The use of CGM increases the safety of the AIST by providing real time level of BG. Albuquerque, New Mexico.
A 25 month old girl was first seen because of growth deceleration beginning at 3 months of age. Birth weight was 64 lbs. and length 19". P. examination was normal except for a height-age of 13 months. After estrogen priming a growth hormone (GH) stimulation test following sequential L-Dopa, arginine and glucagon peaked at 124 nglml from a base-line of 63 nglml. Serum somatomedin-C (Sm-C) concentration, both basal and post-stimulation, measured 0.24 U/ml. (Nl. 1.55.5 U/ml. Measured by Dr. L. Underwood, Univ. of North Carolina, Chapel Hill). At the end of a 24 hour fast her blood glucose was 68 mg%. GH was given for 6 days and her Sm-C level increased to 0.43 U/ml. Four months later her metabolic response to the administration of GH for 6 days showed: releaye of FFA from 757 to 1341 uM/1 and no increase in urinary Ca-H.
Again her Sm-C increased from 0.19 to a peak of .73 U/ml. Prior to GH, her basal GH levels ranged from reached a maximum t o t a l r a d i o a c t i v i t y a t 40-60 min. R a d i o a c t i v i t j accumulated p r i m a r i l y i n f e t a l l i v e r , l u n g , i n t e s t i n e , u t e r u s and l e t e a n a l y s i s was performed on t h e t o t a l f e c a l and u r i n a r y prou c t s i n one animal. U r i n a r y conjugates were p u r i f i e d by XAD-2 nd Sephadex LH-20(MEOH/ETOH 1 : l ) . Three u r i n a r y conjugate f r a ci o n s were obtained, hydrolyzed, and t h e aglycones i d e n t i f i e d by C/MS t o be c i s / t r a n s DES and p o s s i b l y d i e n e s t r o l . The p r i n c i p a l ecal p r o d u c t o~f t e r e x t r a c t i o n and LH-20 p u r i f i c a t i o n ( b e n z -4 13 I 8 to 14 nglml. By RIA her GH produced a parallel dose-response : to pituitary GH standard. After the above study, the patient , was discharged on GH, 0.1 Ulkg three times a week. In the last I 2 months her growth rate has increased from 0.5 to l/cm/month. !
The data on this patient appear to rule out a defect in Sm-C I synthesis or function, as well as factors, either inhibiting GH action or receptor function. The growth deceleration could be explained on the basis of an abnormal circulating GH molecule.
